



PHILIP MORRIS INTERNATIONAL

## PRESS RELEASE

Investor Relations: Media: David Fraser  
New York: +1 (917) 663 2233 Lausanne: +41 (0)58 242 4500  
Lausanne: +41 (0)58 242 4666 Email: David.Fraser@pmi.com  
Email: InvestorRelations@pmi.com

### **PHILIP MORRIS INTERNATIONAL INC. PRESENTS AT 2022 GOLDMAN SACHS GLOBAL STAPLES FORUM**

NEW YORK, May 17, 2022 – Philip Morris International Inc.'s (PMI) (NYSE: PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the Goldman Sachs Global Staples Forum in New York.

The event will be webcast live in listen-only mode, beginning at approximately 9:35 a.m. ET, at [www.pmi.com/2022goldmansachs](http://www.pmi.com/2022goldmansachs).

The audio webcast may also be accessed on iOS or Android devices by downloading PMI's free Investor Relations Mobile Application at [www.pmi.com/irapp](http://www.pmi.com/irapp).

An archived copy of the webcast will be available until 5:00 p.m. ET on Wednesday, June 15, 2022, at [www.pmi.com/2022goldmansachs](http://www.pmi.com/2022goldmansachs).

Presentation slides will also be available on the same site.

#### **Philip Morris International: Delivering a Smoke-Free Future**

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI's IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of March 31, 2022, PMI's smoke-free products are available for sale in 71 markets, and PMI estimates that approximately 12.7 million adults around the world excluding Russia and Ukraine, have already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit [www.pmi.com](http://www.pmi.com) and [www.pmiscience.com](http://www.pmiscience.com).